The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Multiple Sclerosis Drugs Market Research Report 2024

Global Multiple Sclerosis Drugs Market Research Report 2024

Publishing Date : Jan, 2024

License Type :

Report Code : 1804341

No of Pages : 78

Ask Your Query

Report Description
Table of Content

Synopsis

Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems.

The global Multiple Sclerosis Drugs market was valued at US$ 14610 million in 2023 and is anticipated to reach US$ 21240 million by 2030, witnessing a CAGR of 5.0% during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Multiple Sclerosis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiple Sclerosis Drugs.

Report Scope

The Multiple Sclerosis Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Multiple Sclerosis Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Multiple Sclerosis Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

Biogen
Sanofi
Novartis
Teva
Merck KGaA
Bayer
ACORDA
Mallinckrodt

Segment by Type

Injectable Medications
Oral Medications
Others

Segment by Application

Adults
Children

Consumption by Region

North America (United States, Canada)
Europe (Germany, France, U.K., Italy, Russia)
Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
Latin America (Mexico, Brazil, Argentina)
Middle East & Africa (Turkey, Saudi Arabia, UAE)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Multiple Sclerosis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Multiple Sclerosis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Index

1 Multiple Sclerosis Drugs Market Overview
1.1 Product Overview and Scope of Multiple Sclerosis Drugs
1.2 Multiple Sclerosis Drugs Segment by Type
1.2.1 Global Multiple Sclerosis Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Injectable Medications
1.2.3 Oral Medications
1.2.4 Others
1.3 Multiple Sclerosis Drugs Segment by Application
1.3.1 Global Multiple Sclerosis Drugs Market Value by Application: (2024-2030)
1.3.2 Adults
1.3.3 Children
1.4 Global Multiple Sclerosis Drugs Market Size Estimates and Forecasts
1.4.1 Global Multiple Sclerosis Drugs Revenue 2019-2030
1.4.2 Global Multiple Sclerosis Drugs Sales 2019-2030
1.4.3 Global Multiple Sclerosis Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Multiple Sclerosis Drugs Market Competition by Manufacturers
2.1 Global Multiple Sclerosis Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Multiple Sclerosis Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Multiple Sclerosis Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Multiple Sclerosis Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Multiple Sclerosis Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Multiple Sclerosis Drugs, Product Type & Application
2.7 Multiple Sclerosis Drugs Market Competitive Situation and Trends
2.7.1 Multiple Sclerosis Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Multiple Sclerosis Drugs Players Market Share by Revenue
2.7.3 Global Multiple Sclerosis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Multiple Sclerosis Drugs Retrospective Market Scenario by Region
3.1 Global Multiple Sclerosis Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Multiple Sclerosis Drugs Global Multiple Sclerosis Drugs Sales by Region: 2019-2030
3.2.1 Global Multiple Sclerosis Drugs Sales by Region: 2019-2024
3.2.2 Global Multiple Sclerosis Drugs Sales by Region: 2025-2030
3.3 Global Multiple Sclerosis Drugs Global Multiple Sclerosis Drugs Revenue by Region: 2019-2030
3.3.1 Global Multiple Sclerosis Drugs Revenue by Region: 2019-2024
3.3.2 Global Multiple Sclerosis Drugs Revenue by Region: 2025-2030
3.4 North America Multiple Sclerosis Drugs Market Facts & Figures by Country
3.4.1 North America Multiple Sclerosis Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Multiple Sclerosis Drugs Sales by Country (2019-2030)
3.4.3 North America Multiple Sclerosis Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Multiple Sclerosis Drugs Market Facts & Figures by Country
3.5.1 Europe Multiple Sclerosis Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Multiple Sclerosis Drugs Sales by Country (2019-2030)
3.5.3 Europe Multiple Sclerosis Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Multiple Sclerosis Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Multiple Sclerosis Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Multiple Sclerosis Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Multiple Sclerosis Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Multiple Sclerosis Drugs Market Facts & Figures by Country
3.7.1 Latin America Multiple Sclerosis Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Multiple Sclerosis Drugs Sales by Country (2019-2030)
3.7.3 Latin America Multiple Sclerosis Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Multiple Sclerosis Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Multiple Sclerosis Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Multiple Sclerosis Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Multiple Sclerosis Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Multiple Sclerosis Drugs Sales by Type (2019-2030)
4.1.1 Global Multiple Sclerosis Drugs Sales by Type (2019-2024)
4.1.2 Global Multiple Sclerosis Drugs Sales by Type (2025-2030)
4.1.3 Global Multiple Sclerosis Drugs Sales Market Share by Type (2019-2030)
4.2 Global Multiple Sclerosis Drugs Revenue by Type (2019-2030)
4.2.1 Global Multiple Sclerosis Drugs Revenue by Type (2019-2024)
4.2.2 Global Multiple Sclerosis Drugs Revenue by Type (2025-2030)
4.2.3 Global Multiple Sclerosis Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Multiple Sclerosis Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Multiple Sclerosis Drugs Sales by Application (2019-2030)
5.1.1 Global Multiple Sclerosis Drugs Sales by Application (2019-2024)
5.1.2 Global Multiple Sclerosis Drugs Sales by Application (2025-2030)
5.1.3 Global Multiple Sclerosis Drugs Sales Market Share by Application (2019-2030)
5.2 Global Multiple Sclerosis Drugs Revenue by Application (2019-2030)
5.2.1 Global Multiple Sclerosis Drugs Revenue by Application (2019-2024)
5.2.2 Global Multiple Sclerosis Drugs Revenue by Application (2025-2030)
5.2.3 Global Multiple Sclerosis Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Multiple Sclerosis Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Biogen
6.1.1 Biogen Corporation Information
6.1.2 Biogen Description and Business Overview
6.1.3 Biogen Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Biogen Multiple Sclerosis Drugs Product Portfolio
6.1.5 Biogen Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Corporation Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sanofi Multiple Sclerosis Drugs Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Corporation Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Novartis Multiple Sclerosis Drugs Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 Teva
6.4.1 Teva Corporation Information
6.4.2 Teva Description and Business Overview
6.4.3 Teva Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Teva Multiple Sclerosis Drugs Product Portfolio
6.4.5 Teva Recent Developments/Updates
6.5 Merck KGaA
6.5.1 Merck KGaA Corporation Information
6.5.2 Merck KGaA Description and Business Overview
6.5.3 Merck KGaA Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Merck KGaA Multiple Sclerosis Drugs Product Portfolio
6.5.5 Merck KGaA Recent Developments/Updates
6.6 Bayer
6.6.1 Bayer Corporation Information
6.6.2 Bayer Description and Business Overview
6.6.3 Bayer Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Bayer Multiple Sclerosis Drugs Product Portfolio
6.6.5 Bayer Recent Developments/Updates
6.7 ACORDA
6.6.1 ACORDA Corporation Information
6.6.2 ACORDA Description and Business Overview
6.6.3 ACORDA Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 ACORDA Multiple Sclerosis Drugs Product Portfolio
6.7.5 ACORDA Recent Developments/Updates
6.8 Mallinckrodt
6.8.1 Mallinckrodt Corporation Information
6.8.2 Mallinckrodt Description and Business Overview
6.8.3 Mallinckrodt Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Mallinckrodt Multiple Sclerosis Drugs Product Portfolio
6.8.5 Mallinckrodt Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Multiple Sclerosis Drugs Industry Chain Analysis
7.2 Multiple Sclerosis Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Multiple Sclerosis Drugs Production Mode & Process
7.4 Multiple Sclerosis Drugs Sales and Marketing
7.4.1 Multiple Sclerosis Drugs Sales Channels
7.4.2 Multiple Sclerosis Drugs Distributors
7.5 Multiple Sclerosis Drugs Customers
8 Multiple Sclerosis Drugs Market Dynamics
8.1 Multiple Sclerosis Drugs Industry Trends
8.2 Multiple Sclerosis Drugs Market Drivers
8.3 Multiple Sclerosis Drugs Market Challenges
8.4 Multiple Sclerosis Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business:

Since 2015

Pre Sales Support:

24*7

Post Sales Support:

24*7

Turn Around Time:

Usually 2 Hours

Clients Served:

425 and counting

Clients Assisted:

1750 and counting

Client Types:

Govt Projects, Private Companies, Consultant and Individuals

Payment:

Partners with:

Number of reports:

1,000,000 and counting

Custom Research:

Available

Report Availability:

Global and Regional Reports

Report Delivery Format:

Usually PDF

Security:

Latest Life Science Market Reports

Advanced Wound Care-Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Medical Ultrasound-Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Stone Baskets-Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Ureteral Access Sheath-Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Ultrasonic Tissue Ablation System-Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Payments Accepted From

Connect with us at

Complete Secure Website

#socialicons>a span { top: 0px; left: -100%; -webkit-transition: all 0.3s ease; -moz-transition: all 0.3s ease-in-out; -o-transition: all 0.3s ease-in-out; -ms-transition: all 0.3s ease-in-out; transition: all 0.3s ease-in-out;} #socialicons>ahover div{left: 0px;}